Showing 715 results
-
Media Release /
-
Media Release /- Late-breaking data at AAD show Cosentyx® remains superior to Stelara® in achieving almost clear skin (PASI 90) at Week 16 and at one year in 76.2% versus 60.6% of moderate to severe psoriasis…
-
Media Release /
-
Media Release /In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NETApproval helps fulfill unmet need as progressive,…
-
Media Release /
-
Media Release /- Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA)- Approvals for both indications…
-
Media Release /
-
Media Release /- Cosentyx (secukinumab) is the first IL-17A antagonist to complete Phase III studies which demonstrated efficacy and assessed safety in ankylosing spondylitis (AS)(1)- Cosentyx provided improvements…
-
Media Release /
-
Media Release /- 55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults [1]- Additional data presented include analyses on…
